Synapse - Hematologic Malignancies, Division of

Results (13375)

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who underwent allogenic stem cell transplantation (HSCT)

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

Genomic characterization of newly diagnosed acute myeloid leukemia in patients age 60 years and older; A report from the beat AML master trial

Meeting Abstract

Hoff, F. W.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
Blood (2023)

Fulltext@MSK | Save

Intensive induction chemotherapy vs hypomethylating agents + venetoclax (HMA/VEN) in NPM1-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study

Meeting Abstract

Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y. W.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, C.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of therapy sequence on survival outcomes among patients with relapsed or refractory mature T and NK cell neoplasms: A global retrospective cohort study

Meeting Abstract

Sorial, M. N.; Koh, M. J.; Boussi, L.; Han, J. X.; Peng, L.; Eche-Ugwu, I. J.; Duan, R.; Lei, M. M.; Miranda, E.; Chiattone, C.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)

Meeting Abstract

Tomasson, M.; Iida, S.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Martinez-Lopez, J.; Koehne, G.; Otero, P. R.; Prince, H. M.; Viqueira, A.; more...
Blood (2023)

Fulltext@MSK | Save

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) with missing molecular data

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
Blood (2023)

Fulltext@MSK | Save

KB-Lanra 1001: A phase 1b/2 study of safety, PK, PD, and preliminary efficacy of the selective SYK inhibitor lanraplenib in combination with the FLT3 inhibitor gilteritinib in FLT3-mutated R/R AML

Meeting Abstract

Arnan, M.; Patel, A. A.; Esteve, J.; Morris, L.; Schiller, G. J.; Swords, R. T.; Alonso-Dominguez, J. M.; Michaelis, L. C.; Daver, N.; Carvajal, L. A.; more...
Blood (2023)

Fulltext@MSK | Save

Selinexor, ixazomib, pomalidomide and dexamethasone in functionally high-risk multiple myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) sub-protocol Y3

Meeting Abstract

Richter, J.; Zonder, J. A.; Nathwani, N.; Bianchi, G.; Hofmeister, C. C.; Vij, R.; Pianko, M.; Kaur, G.; Hultcrantz, M.; Wozniak, K.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who were treated with hypomethylating agents (HMA)

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
Blood (2023)

Fulltext@MSK | Save

Beat AML S8 Group 2: Gilteritinib (GILT) in combination with decitabine (DEC) and venetoclax (VEN) in untreated FLT3 mutated acute myeloid leukemia (AML) patients age ≥60 with high and low variant allele frequency (VAF)

Meeting Abstract

Liu, Q.; Welkie, R. L.; Huang, Y.; Swords, R. T.; Lin, T. L.; Koenig, K. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; Blum, W.; more...
Blood (2023)

Fulltext@MSK | Save